Skip to content
Skip to navigation menu


First Human Data on Novel Anti-Cancer Protide NUC1031

NUC-1031 is a new experimental agent for solid tumours such as pancreatic cancer.

It entered clinical trials in London in late 2012 and early clinical data were published at ASCO in Chicago on 3rd June 2013.

In 11 patients with progressive disease, the drug was well tolerated with few SAEs.

In 6/11 patients the drug stabilised disease.


There are now plans to expand the study.

NUC-1031 overcomes 3 key known resistance mechanisms of conventional nucleoside drugs:  Transporter - mediated entry, kinase - mediated activation and sensitivity to deactivation via deaminases.

News Article - Tackling cancer

Click here to download a PDF of anti-cancer ProTides such as NUC-1031 and the latest clinical data.